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ABSTRACT Pertussis, or whooping cough, caused by the obligate human pathogen
Bordetella pertussis is undergoing a worldwide resurgence. The majority of studies of
this pathogen are conducted with laboratory-adapted strains which may not be rep-
resentative of the species as a whole. Bioﬁlm formation by B. pertussis plays an im-
portant role in pathogenesis. We conducted a side-by-side comparison of the
bioﬁlm-forming abilities of the prototype laboratory strains and the currently circu-
lating isolates from two countries with different vaccination programs. Compared to
the reference strain, all strains examined herein formed bioﬁlms at high levels. Bio-
ﬁlm structural analyses revealed country-speciﬁc differences, with strains from the
United States forming more structured bioﬁlms. Bacterial hyperaggregation and re-
ciprocal expression of bioﬁlm-promoting and -inhibitory factors were observed in
clinical isolates. An association of increased bioﬁlm formation with augmented epi-
thelial cell adhesion and higher levels of bacterial colonization in the mouse nose
and trachea was detected. To our knowledge, this work links for the ﬁrst time in-
creased bioﬁlm formation in bacteria with a colonization advantage in an animal
model. We propose that the enhanced bioﬁlm-forming capacity of currently circulat-
ing strains contributes to their persistence, transmission, and continued circulation.
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Bordetella pertussis is a human-restricted bacterial pathogen that causes whoopingcough, or pertussis. Pertussis has been reemerging in industrialized countries and
remains endemic in many parts of the world (1). Current pertussis vaccines, while
preventing the severe symptoms of the disease, do not prevent colonization, transmis-
sion, and circulation of the pathogen (2). Reasons suggested for the reemergence of
pertussis are (i) heightened disease awareness, (ii) development of new clinical deﬁni-
tions, (iii) improved diagnostic ability, (iv) poor efﬁcacy of the current commercial
vaccines, and (v) antigenic and genetic shifts in circulating strains (3).
Genetic changes in currently circulating strains of B. pertussis have been primarily
observed in genes which encode vaccine antigens, such as pertussis toxin (PT), ﬁla-
mentous hemagglutinin (FHA), pertactin (PRN), and ﬁmbriae (Fim2 and Fim3) (4–8). In
addition, isolates deﬁcient in the production of PRN, FHA, and PT (9–11) and those
showing increased production of PT have also been reported (12). These genetic and
phenotypic alterations are hypothesized to confer an adaptive advantage to the
circulating strains with respect to survival and transmission among vaccinated popu-
lations (12, 13). Based on these assumptions, it is proposed that the laboratory reference
strains, after more than 6 decades of in vitro passage, do not represent the circulating B.
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pertussis organisms (14). This accentuates the need for research on recently circulating
strains with respect not only to uncovering genomic alterations but also to understanding
phenotypic variations, an area that remains poorly studied.
Bioﬁlms are sessile microbial communities which are enclosed in a self-produced or
host-derived exopolymeric matrix (15). In some bacteria, bioﬁlms promote environ-
mental survival, resulting in an enhanced probability of host contact, while in others,
bioﬁlms are a critical virulence determinant (16, 17). Many bacteria form bioﬁlms during
infection of nonmammalian and mammalian hosts, and bioﬁlms are in general less
susceptible to antimicrobials and host immune components (18–20). Bioﬁlms of B.
pertussis have been observed on a variety of artiﬁcial surfaces and under static, shaking,
and ﬂuid ﬂow conditions (21–25). Microscopically, B. pertussis bioﬁlms are characterized
by formation of spaced cell aggregates followed by the formation of three-dimensional
structures (pillars of bacteria separated by ﬂuid channels or irregularly shaped micro-
colonies) encased in an opaque matrix composed of DNA and polysaccharide (23–27).
In addition to their presence in laboratory settings, bioﬁlms of B. pertussis bacteria have
also been detected in the nose and trachea during experimental infections of mice (24,
25, 27). Correlation between the bioﬁlm-forming ability of B. pertussis and pathogenesis
is provided by the ﬁnding that mutants defective in bioﬁlm formation on artiﬁcial
surfaces fail to protect the bacterial cells from complement-mediated killing, are
attenuated for colonization of the mouse respiratory tract, and are defective in bioﬁlm
formation on the respiratory tract (24, 27, 28). This has led to the hypothesis that bioﬁlm
formation in humans enables escape from immune defenses, resulting in persistence,
transmission, and continued circulation of the bacteria (29). Support for this hypothesis
is provided by microscopy of human tissue explants and respiratory tissues of patients
that reveal bioﬁlm-like structures similar to those formed on artiﬁcial surfaces and in
mouse organs (30–32).
Very little is known about the mechanisms by which B. pertussis bioﬁlm growth has
adapted with respect to time, region, and changing immunization regimens. While
increased levels of bioﬁlm formation by circulating strains from Argentina and Australia
have been reported (33, 34), nothing is known about the bioﬁlm-forming abilities of
circulating isolates from the United States. It is also not known if there are
differences in bioﬁlm structures between strains from different countries. In this
report, we performed a side-by-side comparison of the bioﬁlm-forming abilities of
currently circulating strains from the United States and Argentina with the objective of
determining variations in bioﬁlm-forming capacities and structures. We have also examined
the mechanistic bases for hyperbioﬁlm formation. Finally, we have investigated the rela-
tionship between enhanced bioﬁlm formation and pathogenic phenotypes.
RESULTS
Recently circulating strains of B. pertussis from the United States and Argen-
tina form a thick bacterial ring at the air-liquid interface and display a hyperbio-
ﬁlm phenotype. The bioﬁlm-forming abilities of B. pertussis strains currently circulating
in the United States are not known. During routine roller drum growth in glass tubes
of one such strain (STO1-SEAT0004), we noticed a thick bacterial ring at the liquid-air
interface. In comparison, the reference laboratory strains B. pertussis Tohama I and
Bp536, a Tohama I derivative, formed either a thinner ring or did not form a ring (Fig.
1A). We followed this observation with additional strains from the United States and
Argentina and grew them side by side for comparison purposes. The U.S. strains
resulted in either compact rings at the air-liquid interface or diffused rings over the
glass surface. For the strains that formed diffused rings (strains H973, S49560, and
H897), very little bacterial growth was visible in the liquid phase (Fig. 1A). In compar-
ison, all the Argentinean strains formed compact rings at the air-liquid interface.
We have previously reported a link between the formation of a ring at the air-liquid
interface and bioﬁlm formation in RB50, a Bordetella bronchiseptica reference strain (35).
Additionally, a cystic ﬁbrosis isolate of B. bronchiseptica which formed a thicker ring
than RB50 formed bioﬁlms at higher levels (36). Thus, we hypothesized that recent
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isolates of B. pertussis possess a hyperbioﬁlm phenotype. To test this hypothesis, we
quantiﬁed bioﬁlms formed on polystyrene microtiter plates. After bacteria from the
planktonic phase were discarded and the plates were subjected to extensive washing,
the attached biomass was quantiﬁed by staining adhered bacteria with crystal violet
(CV).
In comparison to Bp536 and BpTohama I, all recent isolates formed high levels of
bioﬁlms on microtiter plates (Fig. 1C). The observed differences in bioﬁlm levels cannot
be explained by enhanced growth since none of the recent isolates displayed signiﬁ-
cantly higher growth than Bp536 in the planktonic phase of bioﬁlm cultures (data not
shown). In combination, these results suggest that recently circulating strains of B.
pertussis form higher levels of bioﬁlms than the model laboratory-adapted strains.
Hyperbioﬁlm-forming strains display hyperaggregative properties. Very little is
known about the mechanisms that contribute to hyperbioﬁlm formation in B. pertussis.
A positive correlation between autoaggregation and bioﬁlm formation has been
reported in bacteria (36, 37). We compared the autoaggregation index (AI) of three
randomly chosen recently circulating strains from Argentina (Bp462, Bp892, and
Bp2751) and the United States (H921, H973, and STO1-SEAT0004) with that of Bp536
(Fig. 2). AI represents the fraction of cells that aggregated (relative to the total cell
population). After 2 h of static incubation, the AI of each of these six strains was 8- to
16-fold higher than that of Bp536. To determine the kinetics of cellular aggregation, the
culture tubes were additionally incubated statically for 5 and 24 h. While at 5 and 24 h
of incubation the AI of Bp536 was higher than that at 2 h, it never reached the values
observed for the clinical strains. For the clinical strains, there was not a signiﬁcant
increase in the AI at 5 and 24 h compared to that at 2 h. We conclude that the clinical
FIG 1 Bioﬁlm-forming capacity of B. pertussis strains. (A) Formation of a bacterial ring at the air-liquid interface of glass culture tubes. (B) Microtiter assay of
bioﬁlm formation at 96 h by B. pertussis strains. Each data point represents the average value of three independent experiments performed in quadruplicates;
error bars indicate standard deviations. Signiﬁcant differences were assessed by one-way ANOVA and Bonferroni posttest. ***, P ,0.001.
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strains form cellular aggregates faster and at higher levels than the reference strain.
These results suggest that the clinical strains utilize hyperaggregation as a means to
enhance their bioﬁlm-forming capacities.
Recently isolated strains of B. pertussis display increased aggregation during
initial surface attachment and form bioﬁlms with enhanced structural complexity.
The approaches used above do not provide detailed information on either the quali-
tative or quantitative strain-speciﬁc differences in bioﬁlm structures. The objective of
the next experiment was to conduct in situ visualization and analyses of differences in
the bioﬁlm three-dimensional (3D) architecture of these strains. For this purpose, each
of the six recently circulating strains and Bp536 were transformed with a green
ﬂuorescent protein (GFP)-coding plasmid, followed by culture on glass coverslips under
agitation conditions, and initial attachment and the bioﬁlms formed were compared.
We ﬁrst examined differences in initial attachment by incubating the strains on the
substrate for 1 h, followed by microscopic observation. As shown in Fig. 3A, all six
recently isolated strains adhered to the surface by forming aggregates, which were
largely absent from Bp536. The formation of small clusters by these strains is consistent
with their higher AI values. Quantiﬁcation of bacteria attached to the glass coverslips
revealed similar numbers of cells for all of the strains, including Bp536 (Fig. 3B). This
suggests that the manner in which recently isolated strains attach to the surface is
different from that of Bp536.
FIG 2 Quantiﬁcation of autoaggregation of B. pertussis strains. Each bar represents the mean value of at least three
independent experiments performed in duplicate. Error bars represent standard deviations. Statistical differences
were assessed by one-way ANOVA and Bonferroni posttest. ***, P ,0.001.
FIG 3 Fluorescence microscopy and quantiﬁcation of early bacterial attachment. (A) Attached GFP-labeled bacterial cells were observed by
ﬂuorescence microscopy. (B) Cells were counted by means of the ITCN plug-in for ImageJ. Data are average values of at least three independent
experiments performed in duplicates. Four random regions were chosen for bacterial counting. Error bars indicate standard deviations.
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To observe and quantify the 3D structures of bioﬁlms, the growth of bioﬁlms was
examined by confocal laser scanning microscopy (CLSM) at 24-h intervals over a time
period of 96 h (Fig. 4). After 24 h of growth of Bp536, almost the entire surface area was
completely covered with green cells which appeared to exist as a uniform monolayer.
In contrast, all six recently isolated strains were present on the cover glass surface in the
form of clustered cells, and many areas of the cover glass were observed to be
unoccupied. For these strains, small pillars of cells, a characteristic architectural feature
of Bordetella bioﬁlms, were also found (23, 27). At 48 h of growth, while minute cell
clusters and thin pillars were observed for Bp536, the recently isolated strains contin-
ued to increase in thickness and cell density, resulting in the visualization of thicker and
more structured bioﬁlms. After 72 and 96 h of culture, while Bp536 achieved a more
complex bioﬁlm structure involving the formation of some water channels, the recently
isolated strains continued to form complex bioﬁlm structures with large and irregularly
shaped clusters and longer cell pillars.
Interestingly, in addition to structural differences, region-speciﬁc variations in the
bioﬁlm features were also observed among the recently isolated strains. At time points
later than 24 h, for the strains isolated in the United States (H921, H973, and STO1-
SEAT0004), large and irregularly shaped cell aggregates continued to be observed
during the entire time course of bioﬁlm formation, whereas for the Argentinean strains
(Bp462, Bp892, and Bp2751) almost the entire surface area was green, revealing a thick
uniform layer of cells.
Quantitative analysis of bioﬁlm architecture. In order to achieve a quantitative
assessment of the observed microscopic differences in bioﬁlm structures, CLSM-
generated images were analyzed for four variables of bioﬁlm architecture—biomass,
maximum thickness, average thickness, and roughness coefﬁcient—by the COMSTAT2
image analysis program (Fig. 5) (38). Overall, and at all time points of bioﬁlm formation,
maximum thickness and average thickness were signiﬁcantly higher for the recently
isolated strains than for Bp536. The only exception was Bp892, for which the maximum
bioﬁlm thickness was not signiﬁcantly different from that of Bp536 at 24 h. Biomass was
signiﬁcantly higher for all clinical isolates at 96 h. The roughness coefﬁcient, a measure
of how much the bioﬁlm thickness varies and thus a measure of bioﬁlm heterogeneity,
varied the greatest between Bp536 and the clinical strains. In general, for the Argen-
tinean strains, the roughness coefﬁcient was lower than that of Bp536, whereas for the
U.S. strains it was higher at many of the time points. The difference in roughness
coefﬁcients between the Argentinean and U.S. strains correlated with microcolonies
separated by empty spaces, as observed by CLSM. Overall, these results suggest that
the B. pertussis clinical strains form bioﬁlms differently than the reference strain and
that differences in bioﬁlm structures are observed between strains isolated from United
States and Argentina.
Dispersal of bioﬁlms by pronase E, DNase I, and sodiummetaperiodate. Previously,
we have shown that proteins, DNA, and polysaccharides are components of the B.
pertussis bioﬁlm matrix and promote the stability of bioﬁlms formed by Bp536 (21,
23–25). To address the functional roles of these components in stabilizing the bioﬁlms
of the recently isolated strains, we studied the effect of pronase E, DNase I, and sodium
metaperiodate (NaIO4) on dispersal of preformed mature bioﬁlms. Ninety-six-hour-old
bioﬁlms were incubated either with these reagents or with the respective buffer
solutions for 2 h at 37°C, followed by CV staining to quantitate the stained biomass.
Compared to Bp536, for ﬁve of the six recently isolated strains, pronase E treatment led
to low levels of bioﬁlm dispersal (50.3% for Bp536 and varying between 25.3 and 32.3%
for Bp462, Bp2751, H921, H973, and STO1-SEAT0004). For strain Bp892, however,
pronase E treatment was sufﬁcient to disperse the bioﬁlms to levels similar to those
observed for Bp536 (Fig. 6A).
Sodium metaperiodate treatment resulted in two different levels of bioﬁlm disper-
sal. For three of the recently isolated strains (Bp462, Bp2751, and H921), dispersion of
bioﬁlms was similar to that observed for Bp536 (varying between 31.7 and 37.6%). For
Hyperbioﬁlms and Enhanced Bordetella Pathogenesis Infection and Immunity
December 2017 Volume 85 Issue 12 e00373-17 iai.asm.org 5
 on Septem
ber 4, 2019 by guest
http://iai.asm
.org/
D
ow
nloaded from
 
FIG 4 CLSM micrographs of B. pertussis bioﬁlms. GFP-labeled bacterial strains were grown on cover
glasses in six-well plates for the designated time points. Bioﬁlms were visualized in situ by CLSM
microscopy. CLSM image stacks were acquired at 0.9-mm z-intervals; xy and xz representative focal planes
are shown.
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the other three strains (Bp892, H973, and STO1-SEAT0004), however, NaIO4 treatment
resulted in signiﬁcantly higher levels (varying between 60.4 and 66.9%) of bioﬁlm
dispersal (Fig. 6B).
Similar to results for Bp536, for four of the recently isolated strains (Bp892, Bp2751,
H973, and STO1-SEAT0004), greater than 50% of bioﬁlms were dispersed by treatment
with DNase I. For Bp892, incubation with DNase I led to greater than 85% dispersal. For
two of the isolates (Bp2751 and Bp462), DNase I had a somewhat moderate effect (35.4
and 40%, respectively) on bioﬁlm dispersal (Fig. 6C). The various levels of bioﬁlm
dispersal as a result of incubation with the above chemicals are probably due to
differences in bioﬁlm formation between various strains. Taken together, these results
suggest that, similar to Bp536, recently isolated strains have protein, DNA, and carbo-
hydrate content in their bioﬁlm matrices.
Recently isolated strains exhibit differential expression of Bordetella factors
involved in bioﬁlm formation and pathogenesis. Critical among factors that con-
tribute to robust bioﬁlm formation in B. pertussis are FHA, adenylate cyclase (AC) toxin,
and Bps polysaccharide (24, 27, 39). FHA and AC toxin promote and inhibit B. pertussis
bioﬁlm formation, respectively (24, 39). Bps is critical for the stability and maintenance
of the three-dimensional structure of B. pertussis bioﬁlms (27). In addition to their roles
in bioﬁlm formation, FHA, AC toxin, and Bps also function as critical virulence factors for
B. pertussis (27, 28, 40–42). Thus, we quantitated the expression levels of these factors
in the clinical strains. As a negative control, the Bvg2 phase-locked and the Δbps strains
were used. These strains do not express FHA or AC toxin and Bps, respectively.
We performed a whole-cell enzyme-linked immunosorbent assay (ELISA) to
determine the levels of cell surface-associated FHA. As shown in Fig. 7A, all of the
recently isolated strains produced signiﬁcantly larger amounts (between 2.6- and
FIG 5 COMSTAT analyses of B. pertussis bioﬁlms. CLSM image stacks were acquired at 0.9-mm z-intervals and analyzed by COMSTAT2. Average values of
parameters from CLSM image stacks derived from at least three independent experiments are shown with standard errors. P values were determined
using two-way ANOVA. Average thickness (A) and maximum thickness (B) were calculated only on the biomass (without counting the uncovered area).
Biomass values (C) represent the biomass volume divided by the area of the substratum. Roughness coefﬁcients (D) represent the variability in the
heights of the bioﬁlms. *, P ,0.05; **, P ,0.01; ***, P ,0.001.
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3.3-fold) of FHA than Bp536. The expression of FHA was at background levels in this
strain. As shown in Fig. 7B, all recent isolates displayed lower AC toxin activity than
Bp536.
Changes in the expression of the bps locus were determined by quantitative
reverse-transcription PCR (qRT-PCR) by comparing levels of the bpsA transcripts in
Bp536 and the recently circulating strains. In two of the six recently isolates, expression
of bpsA was signiﬁcantly higher (5.4- and 1.6-fold higher in H921 and H973, respec-
tively) (Fig. 7C). In four other strains, there were no signiﬁcant differences in the
expression levels of bpsA transcript. Bps production was detected by immunoblotting
in all of the recently isolated strains (Fig. 7D). Using an ELISA, we failed to precisely and
reproducibly quantitate Bps levels in the recently circulating isolates. Taken together,
these results suggest that hyperbioﬁlm formation in recently isolated strains is associ-
ated with increased expression of genes/proteins that promote bioﬁlm formation and
decreased activity of the protein that inhibits bioﬁlm formation.
Recently isolated strains exhibit hyperadhesion to respiratory epithelial cells
of human origin. The recently isolated strains attached and formed higher levels of
bioﬁlms on artiﬁcial surfaces. Additionally, FHA was produced at higher levels in the
clinical strains. FHA promotes the adherence of B. pertussis to epithelial cells (43). We
hypothesized that, compared to Bp536, the recently circulating strains will exhibit
increased cellular adherence to epithelial cells. To test this hypothesis, we compared
attachment levels of these strains to human alveolar epithelial cells (A549). As shown
in Fig. 8, all of the recently isolated strains adhered to A549 cells to a greater extent
FIG 6 Bioﬁlm dispersal by matrix-dissolving agents. Ninety-six-hour bioﬁlms were treated with pronase E in Tris buffer (A), with 40 mM sodium
metaperiodate (NaIO4) in H2O (B), and with DNase I in reaction buffer (C) for 2 h at 37°C (ﬁlled bars). Bioﬁlms were treated with the respective reaction
buffers as controls (open bars). Bioﬁlm reduction is presented as a percentage of the value for the respective strain incubated with buffer only. Average
values are shown from one representative assay of three independent replicates, with their respective standard deviations. Signiﬁcance was assessed
by two-way ANOVA. *, P ,0.05; **, P ,0.01; ***, P ,0.001.
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than did Bp536. However, these differences in cellular attachment levels were statisti-
cally signiﬁcant only for the strains Bp462, H973, and STO1-SEAT0004. As expected, the
Bvg2 phase-locked strain which does not express FHA and other Bordetella adhesins
exhibited very low levels of attachment to the epithelial cells.
FIG 7 Determination of the levels of bioﬁlm-associated factors/genes in B. pertussis strains. (A) Cell surface-associated FHA
determination by ELISA. Average values of three replicates are presented with the respective standard deviations. (B) AC
toxin activity quantiﬁcation. AC toxin levels were assessed by enzymatic activity as described earlier (69). (C) bpsA
expression and production. bpsA transcript levels were determined by qPCR and the Pfafﬂ method. *, P ,0.05; **, P ,0.01;
***, P ,0.001. (D) Dot blot of Bps. Production of Bps was detected as described previously (27).
FIG 8 Adherence of B. pertussis strains to epithelial cells. Adhesion assays were performed with A549
epithelial cell lines. Each strain was incubated at a multiplicity of infection of 10. Results are expressed as the
proportion of adherent bacteria to the amount of the original inoculum. Each data point is the average of
three independent experiments performed in duplicate. Error bars indicate the standard deviations. Statistical
differences were assessed by one-way ANOVA (P , 0.0001) and Student’s t test with a Bonferroni post hoc
correction. *, P ,0.05; **, P ,0.01; ***, P ,0.001. Bp Bvg2, B. pertussis Bvg2 phase-locked strain.
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Enhanced colonization of the mouse respiratory tract by recently isolated
strains. To determine the role of a hyperbioﬁlm phenotype in affecting the outcome
of infection, we compared the colonization of Bp536 to the mouse respiratory tract to
that of Bp462 and STO1-SEAT0004. Groups of 8- to 10-week-old male and female mice
were intranasally inoculated separately with the strains, and the bacterial loads of the
nose, trachea, and lungs were determined at 4 and 7 days postinoculation (dpi) (Fig. 9).
Consistent with previously published results, high bacterial loads of Bp536 were
recovered from all three organs at 4 dpi (Fig. 9A). Compared to Bp536, while the two
clinical strains colonized the nose and trachea at high numbers at 4 dpi, no signiﬁcant
differences were found in bacterial numbers harvested from the lungs between any of
the strains at this time point. At 7 dpi, all three strains continued to colonize the
respiratory organs at high numbers, and the two recent isolates colonized the nose at
higher numbers than Bp536 (Fig. 9B). Previously, we have shown the existence of
bioﬁlms of B. pertussis in the mouse nose and trachea (24, 25, 27) and found that
mutants defective in bioﬁlm formation in vitro are defective in colonization of the
respiratory tract (24, 27). Thus, we propose that the observed hyperbioﬁlm phenotype
of recent isolates contributes to the enhanced respiratory tract colonization.
DISCUSSION
The majority of studies on the biology and pathogenesis of the obligate human
pathogen B. pertussis have been conducted with the strain BpTohama I and its
derivatives. This strain, originally isolated in Japan in the 1950s, is a major source of
pertussis vaccines. It has been suggested that it does not represent B. pertussis species
(14). Although considerable effort is currently being dedicated toward genome se-
quencing and categorization of genomic differences between circulating clinical strains
and domesticated laboratory strains, very little is known regarding their physiological
and pathogenic differences. Bioﬁlm formation is considered to be a survival strategy
that allows enhanced respiratory tract colonization, persistence, transmission, and
circulation of B. pertussis in humans (24, 27–29). Characterization of the underlying
molecular mechanisms, factors involved, and the assessment of the relationship be-
tween bioﬁlms and pathogenesis in currently circulating clinical isolates is important for
the development of more effective vaccines and therapeutic alternatives to stem the
resurgence of pertussis.
In this study, we utilized B. pertussis strains isolated during the period of 2001 to
2012 across two countries, Argentina and the United States. While acellular vaccines are
exclusively employed for immunization in the United States, whole-cell vaccines are
FIG 9 Colonization of mouse respiratory tract by Bp536, Bp462, and STO1-SEAT0004. Groups of C57BL/6 mice were
intranasally inoculated with approximately 5 3 105 CFU in 50 ml of PBS. At 4 (A) and 7 (B) days postinoculation,
animals were sacriﬁced, and bacterial loads were determined in nasal septum, trachea, and lung. Horizontal bars
represent the average values for each group. Signiﬁcance was analyzed by means of one-way ANOVA and
Dunnett’s posttest. *, P ,0.05; **, P ,0.01; ***, P ,0.001.
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used for the ﬁrst ﬁve immunizations, followed by the acellular vaccine as a booster, for
11-year-olds in Argentina. Despite having two different routine pertussis immunization
programs, both of these countries have experienced a steady increase in pertussis cases
over the last decade. Thus, simultaneous comparison of recently circulating strains from
these two countries is likely to shed light not only on variations in microbial pathogenic
mechanisms but also on how bacterial pathogens evolve to evade and escape from
vaccine-induced immunity.
In comparison to the reference strains, all of the strains, irrespective of the region
and the year of isolation, were characterized by hyperbioﬁlm formation. We propose
that hyperbioﬁlm formation is a highly conserved strategy employed by B. pertussis for
surface adherence and that this phenotype is maintained independent of the types of
vaccines used for immunization.
The mechanisms underlying increased bioﬁlm formation and strain-dependent
differences in the bioﬁlm structures of B. pertussis were unknown until now. In this
report, a positive correlation was found between bacterial hyperaggregation and
enhanced bioﬁlm formation in six of the selected currently circulating strains, suggest-
ing that both of these processes depend on the same physical adhesive forces and that
these strains may contain similar extracellular matrices that lead to enhanced cell-cell
interactions. Structural analyses of bioﬁlms by CLSM revealed signiﬁcant regional
differences in the bioﬁlm architectures. In general, the Argentinean strains formed more
compact and regularly shaped bioﬁlms, while the U.S. strains developed distinct
microcolonies and more structured and heterogeneous bioﬁlms. The development of
complex bioﬁlm architecture has been linked to enhanced antimicrobial properties (44,
45). It remains to be determined if the differences in bioﬁlm architectures between
strains from the United States and Argentina are due to bacterial adaptation to
dissimilar vaccination programs and if these result in differential resistance to compo-
nents of host immunity.
FHA and AC toxin have been shown to positively and negatively control bioﬁlm
formation in B. pertussis, respectively (24, 39). By promoting cell surface and inter-
bacterial adhesion, FHA promotes bioﬁlm formation (24). AC toxin inhibits B. pertussis
bioﬁlm formation by directly interacting with FHA (39). We found an inverse correlation
between FHA production and AC toxin activity in recently isolated clinical strains which
were characterized by the production of higher levels of FHA and lower AC toxin
activity. The observed differences in FHA levels and AC toxin activity could also explain
the hyperaggregating property of the clinical strains. FHA is responsible for autoag-
gregation in B. pertussis (46), and autoaggregation in B. pertussis is inhibited by addition
of AC toxin (39). We propose that by inversely controlling the production of a bioﬁlm-
inhibitory and -promoting factor, the clinical strains are able to display higher levels of
autoaggregation and bioﬁlm formation. A similar link between production of FHA and
AC toxin and hyperbioﬁlm formation was recently reported by us in a cystic ﬁbrosis
isolate of B. bronchiseptica which was characterized by higher expression of fhaB and
the absence of the cyaA gene from the genome (36). To our knowledge, this report is
the ﬁrst to document the lower AC toxin activity in recently circulating strains of B.
pertussis. It will be highly informative to determine if this property is conserved in a
larger number of strains and in strains isolated from other countries. The observed
differences in the levels of FHA and AC toxin activity raise an interesting question
regarding the mechanism by which the regulation of these two genes is maintained in
the clinical strains.
The Bordetella bpsABCD locus required for the synthesis of the Bps polysaccharide is
critical for the stability and maintenance of the complex architecture of bioﬁlms (23, 47,
48). Two of the hyperbioﬁlm formers had higher levels of bpsA expression than Bp536,
whereas in four others the expression levels of this gene were similar. All of the strains
produced Bps. Targeted mutagenesis will offer detailed insights on the relative contri-
butions of individual genes in hyperbioﬁlm formation of these strains.
A striking result from the present study is the discovery of a link between the
hyperbioﬁlm-forming ability of bacteria and enhanced pathogenic phenotypes. First,
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many of the hyperbioﬁlm-forming strains from both Argentina and the United States
exhibited increased adherence to human epithelial cells. The increased cellular adher-
ence of the recently isolated strains is most likely a direct result of enhanced production
of FHA. FHA facilitates attachment of B. pertussis to a variety of multiple cell types and
extracellular structures in the respiratory epithelium (43, 49, 50).
Given the central role that bioﬁlms play in promoting enhanced resistance to
chemicals, antimicrobial compounds, and components of host immunity, it is reason-
able to hypothesize that a hyperbioﬁlm phenotype will result in better survival in host
tissues and organs. A few studies have directly tested this hypothesis, and the results
obtained were generally not supportive. Bacterial mutants that display increased
bioﬁlm formation are either equally or signiﬁcantly less virulent than wild-type strains
(51–57). Similarly, while the increased in vitro cellular adherence of the hyperbioﬁlm-
forming clinical strains should in theory lead to enhanced colonization in an animal
model, previously we did not ﬁnd this to be the case. A clinical strain of B. bronchisep-
tica, despite exhibiting higher levels of bioﬁlms and epithelial cell adherence than the
laboratory strain, was deﬁcient in early colonization of the mouse respiratory tract (36).
In this study, two of the recently isolated strains that displayed hyperbioﬁlm and
hyperadherence phenotypes colonized the mouse nose and trachea at higher numbers.
Whether the hyperbioﬁlm-forming ability observed on artiﬁcial surfaces and higher
bacterial numbers of the clinical strains in mouse nose and trachea correlate with
quantitative and qualitative differences in nasal and tracheal bioﬁlms needs to be
determined.
In conclusion, we have for the ﬁrst time demonstrated an association between
higher levels of bioﬁlm formation in bacteria with enhanced colonization in an animal
model of infection. Based on the data obtained, we propose some mechanistic expla-
nations for the continued circulation of B. pertussis and the resurgence of pertussis.
Hyperaggregative, hyperbioﬁlm, and hyperepithelial cell-adhesive properties of the
clinical strains most likely result in the formation of robust organ-adherent bioﬁlm
communities in the nose and trachea. These bioﬁlm-borne bacteria would survive
better in the respiratory tract because of evasion of and escape from immune defenses
leading to nasopharyngeal carriage. Droplet or airborne routes are principal ways of B.
pertussis transmission. Efﬁcient generation and optimal particle size are critical deter-
minates for successful host-host transmission. Droplets are generally deﬁned as being
$5 mm size, and droplet sizes at diameters of 30 mm or greater can remain suspended
in the air. B. pertussis is a relatively small bacterium (0.4 to 0.8 mm) (58). We speculate
that increased aggregation of the clinical strains in the respiratory tract could generate
optimally sized particles which will resist desiccation during transmission of infectious
particles. Thus, a combination of enhanced respiratory tract survival followed by
enhanced transmission has led to the resurgence of pertussis. Finally, the conservation
of a hyperbioﬁlm phenotype in B. pertussis strains in multiple continents with different
vaccine and immunization schedules highlights the urgent need for continued research
and development of alternative therapeutics and vaccines targeted toward the bioﬁlm
lifestyle.
MATERIALS AND METHODS
Ethics statement. Housing, husbandry, and experiments with animals were carried out in accor-
dance with the guidelines approved by the Institutional Animal Care and Use Committee of Wake Forest
School of Medicine. Bacterial strains were collected by regional Microbiology Laboratories in Argentina
and at Wake Forest School of Medicine as part of the patients’ usual care, without any additional testing
for the present investigation. Deidentiﬁed organisms were provided to the investigators, and the
information received by the investigators was not individually identiﬁable. The research does not meet
the Federal deﬁnition of research involving human subject research as outlined in the Code of Federal
Regulations (59).
Strains and growth conditions. Strains used in this work are listed in Table 1. Strains S49560 and
M3984 were isolated in 2005 at the Wake Forest School of Medicine (WFSM) from a 38-day-old female
baby (with coughing spells, apnea events, and cyanosis) and a 7-week-old female baby (with cough and
respiratory distress), respectively. Argentinean strains were isolated at La Plata Children’s Hospital
(Hospital Interzonal de Agudos Especializado en Pediatría Sor María Ludovica), and the patient ages
varied between 6 and 16 weeks old. B. pertussis strains were maintained on Bordet-Gengou agar (BGA)
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supplemented with 10% (vol/vol) deﬁbrinated sheep blood. For liquid cultures, strains were grown in
Stainer-Scholte (SS) broth (35, 60). Escherichia coli strains were grown in Luria-Bertani medium. When
appropriate, antibiotics were added to maintain plasmids and for strain selection on agar plates:
streptomycin, 50 mg ml21; kanamycin, 25 mg ml21; cephalexin, 40 mg ml21.
Bioﬁlm formation assays. For microtiter dish assay of bioﬁlm formation, 100 ml of bacterial
suspension prepared at an optical density at 650 nm (OD650) of 1.0 was incubated statically for 4 h at
37°C. After this initial attachment step, medium was carefully removed, fresh SS medium was added, and
plates were incubated at 37°C with shaking at 90 rpm. After every 24 h of growth, medium was replaced
with fresh SS medium. After the period of incubation indicated in the ﬁgures and ﬁgure legends,
planktonic bacteria were removed, and the OD650 was measured. Adhered biomass was quantiﬁed by CV
staining as previously described (61). Three independent experiments with quadruplicates for each strain
were performed.
Autoaggregation assay. Bacteria were cultured in SS medium with heptakis(2,6-di-O-methyl-b-
cyclodextrin) and supplement for 24 h (62). Cells were harvested by centrifugation, washed, and
resuspended in only SS medium at an OD650 of 1.0, followed by static incubation at room temperature.
At 2, 5, and 24 h of incubation, 100 ml of the medium was taken out from the top layer of the suspension,
and the OD650 was measured. The autoaggregation index (AI) was calculated as follows: (ODt0 2
ODt)/ODt0, where ODt0 is the initial OD measurement and ODt is the OD measured at a designated time
point t. Three independent experiments were performed in duplicate for each sample. Statistical
signiﬁcance was evaluated by one-way analysis of variance (ANOVA).
Transformation of B. pertussis strains with plasmid pGBSp1-GFP. B. pertussis strains were
transformed by electroporation (63) of plasmid pGB5P1-GFP (64). Bacterial colonies were selected on BGA
containing kanamycin and cultured in SS medium. GFP expression was conﬁrmed by ﬂuorescence
microscopy.
Adhesion to abiotic surfaces. GFP-labeled strains were grown overnight in SS medium with
kanamycin and used to prepare cell suspensions at an OD650 of 0.2. Two milliliters of bacterial suspension
was added to individual wells of six-well cell culture plates containing cover glasses (22 by 22 mm), and
after 1 h of incubation at 37°C, each well was washed twice with phosphate-buffered saline (PBS). Cover
glasses were mounted on glass slides with ProLong Gold antifade reagent (Invitrogen) and observed with
a Nikon Eclipse microscope. Adhered cells were counted with the ITCN (image-based tool for counting
nuclei) plug-in (65) for ImageJ (66). At least three independent experiments were performed in duplicate
for each strain, where four random regions were chosen for bacterial counting.
Structural analysis of bioﬁlms by CLSM. Bioﬁlms were grown on 22- by 22-mm cover glasses in
six-well plates in SS medium supplemented with kanamycin. Each well was inoculated with a bacterial
suspension at an OD650 of 1.0, followed by 4 h of static incubation at 37°C; then the suspensions were
removed, and fresh medium was added. After every 24 h of growth, the medium was replaced with fresh
SS medium. Cover glasses were washed, mounted as described above, stored at 4°C for 24 h, and
visualized with a Nikon Ti-Eclipse confocal microscope. Quantitative data corresponding to structural
features of the bioﬁlms were acquired with COMSTAT2 (38). Each experiment was performed at least
three times.
TABLE 1 Strains used in this study
Strain Source or description Year of isolation (reference)
BpTohama I Laboratory reference strain 1954
Bp536 Laboratory reference strain, Smr derivative
of Tohama I
(72)
Bp369 (Bvg2) derivative of Tohama III (73)
ΔfhaB strain ΔfhaB mutant (74)
Δbps strain Δbps mutant (27)
Bp462 Argentina 2006
Bp479 Argentina 2007
Bp612 Argentina 2008
Bp892 Argentina 2007
Bp955 Argentina 2001
Bp1938 Argentina 2003
Bp2524 Argentina 2004
Bp2723 Argentina 2001
Bp2751 Argentina 2004
Bp2770 Argentina 2001
H918 USA 2012 (75)
H921 USA 2012 (75)
H973 USA 2012 (75)
H987 USA 2012 (75)
I002 USA 2012 (75)
STO1-CHOC0008 USA 2010 (75)
STO1-SEAT0004 USA 2011 (75)
M3984 USA 2005
S49560 USA 2005
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Enzymatic treatment of bioﬁlms. Bioﬁlms grown in microtiter plates for 96 h were treated with
DNase I (40 U) (25), pronase E (1 mg/ml), or sodium metaperiodate (40 mM, pH 5.0) for 2 h at 37°C.
Controls were treated with respective reaction buffers: 10 mM Tris-HCl, pH 7.6, 2.5 mM MgCl2, and 0.5
mM CaCl2 for DNase I; 10 mM Tris-HCl, pH 7.5, for pronase E; and H2O for sodium metaperiodate. After
each enzymatic treatment, the remaining bioﬁlm was quantiﬁed by staining with CV.
ELISA. FHA production was determined by enzyme-linked immunosorbent assay (ELISA) as previ-
ously described (67, 68). Brieﬂy, 100 ml of heat-inactivated cells (OD650 of 0.05 for FHA) in PBS was added
to strip plates (EIA/RIA Stripwell plate; Corning) and incubated overnight at 4°C; cells were washed with
PBS buffer containing 0.05% Tween 20 (PBST), followed by blocking with 5% skim milk for 1 h at 37°C.
A polyclonal serum raised in mouse (1:20,000 dilution) against puriﬁed FHA (Kaketsuken) was used as a
primary antibody. Antibody dilutions were prepared in 5% skim milk in PBST. As a control, nonimmune
serum was used. After 2 h of incubation at 37°C, plates were washed with PBST, and the secondary
antibody (horseradish peroxidase [HRP]-conjugated goat anti-mouse IgG; 1:20,000 dilution) was added,
followed by incubation for 2 h at room temperature. After plates were washed with PBST, 100 ml of
tetramethyl-benzidine (TMB; Sigma) was added to each well and incubated in the dark for 20 min,
followed by addition of 1 M H2SO4 to stop the reaction. Absorbance was measured at 450 nm. For
FHA protein quantiﬁcation, a linear standard curve was prepared using different concentrations of
puriﬁed FHA.
Quantitation of adenylate cyclase enzymatic activity. B. pertussis clinical strains were grown to
mid-log phase, to an OD650 of 0.7 to 0.8. AC activity was determined as previously reported (69).
RNA preparation, cDNA synthesis, and qPCR. B. pertussis strains were grown under shaking
conditions to an OD650 of 1.0, placed immediately on ice, and centrifuged at 4°C, and the bacterial pellets
were lysed in RLT buffer (Qiagen). RNA was puriﬁed using a Qiagen RNeasy kit and treated with RQ1
DNase I (Promega) for 45 min at 37°C to obtain DNA-free RNA. cDNA was synthesized with random
hexamers and SuperScriptIII reverse transcriptase (Invitrogen) as described earlier (70). Differential
expression of genes between the strains Bp536, Bp462, Bp892, Bp2751, H921, H973, and STO1-SEAT0004
was analyzed by means of the Pfafﬂ method (71), following real-time PCR quantiﬁcation with SYBR green.
rpoD was used as a housekeeping gene for normalization. Quantitative PCR (qPCR) analysis was performed
with three biological and two technical replicates. Primers used for qPCR are listed in Table 2.
Immunoblot analyses. Detection of Bps by immunoblotting was performed as previously described
(23, 27). The membrane was probed with a 1:5,000 dilution of a goat antibody raised against Staphylo-
coccus aureus poly-N-acetyl-b-(1-6)-glucosamine (PNAG) conjugated to diphtheria toxoid. The secondary
antibody used was a horseradish peroxidase-conjugated mouse anti-goat immunoglobulin G (IgG)
antibody (Pierce) diluted 1:20,000 and detected with an Amersham ECL (enhanced chemiluminescence)
Western blotting system.
Bacterial adhesion to epithelial cells. Human alveolar epithelial cells (A549) were cultured at 37°C
under 5% CO2 in Dulbecco’s modiﬁed Eagle’s medium supplemented with 10% fetal bovine serum (FBS)
and 4 mM L-glutamine. A549 cells were harvested at 90% conﬂuence, and approximately 2 3 105 cells
were seeded in 24-well cell culture plates, followed by incubation overnight. A total of 2 3 106 CFU of
B. pertussis was added to the wells and centrifuged at 900 rpm for 5 min to facilitate contact between
bacteria and epithelial cells; the plates were then incubated at 37°C for 15 min to allow bacterial
attachment to A549 cells. The medium was removed, and the wells were washed four times with sterile
PBS to remove any nonattached bacteria. The eukaryotic cells were then lysed with 0.05% saponin, and
the mixture was plated on BGA containing 10% blood and cephalexin for enumeration of attached
bacteria. Adhesion assays were performed in duplicate three times.
Animal experiments. Groups of ﬁve to eight 8- to 10-week-old male and female C57BL/6 mice were
used for all the experiments. Mice were intranasally inoculated with 50 ml of a bacterial suspension with
approximately 5 3 105 CFU of the B. pertussis strains indicated in the ﬁgures. At 4 days postinfection,
mice were sacriﬁced, and the nasal septum, trachea, and three right lung lobes were harvested. Tissues
were homogenized in PBS containing 1% casein and plated on BGA containing 10% blood and
streptomycin (for Bp536) or cephalexin (for clinical strains). After 3 to 5 days of growth at 37°C, colonies
were enumerated. Statistical signiﬁcance was determined by one-way ANOVA, and data were deter-
mined to be signiﬁcant at a P value of ,0.05.
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TABLE 2 Primer sequences
Primera Sequence
rpoD-Fw 5=-ATGGGCATCCGCTTCACG
rpoD-Rv 5=-CTTCGTCCAACACCCAC
bpsA-Fw 5=-CGCTGCTGACCATGGATTT
bpsA-Rv 5=-CTGGTGTACAGCATGGTGTTGA
aFw, forward; Rv, reverse.
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